Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZABRIGHT-BLADDER01
CTR20255145Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in urothelial carcinoma (UC), transitional cell carcinoma (TCC), sponsored by Bristol Myers Squibb. Started Mar 2026; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
urothelial carcinoma (UC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20255145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255145.